Integrated Multi-Omics Analysis of Treatment-Naive Patients With Chronic HBV Infection
Key facts
- Who runs it
- Beijing Municipal Administration of Hospitals
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 1 Oct 2028
- Type of study
- Observational
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Persistent hepatitis B surface antigen (HBsAg) positivity for more than 6 months
- Diagnosis of chronic hepatitis B virus (HBV) infection
- No previous treatment with nucleos(t)ide analogues or interferon before the study observation time point
- No previous use of immunomodulatory agents or hepatoprotective and anti-inflammatory medications that may significantly affect the study-related indicators before the observation time point
- Availability of demographic, clinical biochemical, and virological data required for the study
- Availability of stored serum samples that can be accurately matched with clinical data and meet the quality requirements for subsequent analyses
- For existing cases, reuse of clinical data and samples must comply with the ethics committee's approval and applicable informed consent requirements. Prospectively enrolled participants must provide written informed consent
Who cannot take part
- Concurrent autoimmune liver disease
- Coinfection with other viral hepatitis infections, including hepatitis A, C, or E
- Alcohol-associated liver disease
- Incomplete clinical records, virological data, or stored serum samples that do not meet the requirements for the planned analyses
- Advanced liver cirrhosis
- Hepatocellular carcinoma
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Hepatitis B
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single-center, cross-sectional, observational study involving approximately 1,000 treatment-naive patients with chronic hepatitis B virus (HBV) infection at Beijing Ditan Hospital, Capital Medical University.
Read full original descriptionShow less
The study aims to investigate the relationship between HBV genetic characteristics, host molecular profiles, and clinical features of chronic HBV infection. Clinical and laboratory information, including liver function tests, HBV DNA levels, hepatitis B surface antigen (HBsAg) levels, and liver fibrosis assessments, will be collected from eligible participants.
Existing clinical data and stored serum samples will be used when authorized and approved by the Ethics Committee. Newly enrolled participants will contribute residual serum samples obtained after routine clinical testing. No additional blood collection or experimental treatment will be required for this study.
HBV whole-genome sequencing data will be analyzed to characterize viral genotypes, mutations, and viral diversity. In approximately 300 selected participants, serum metabolomics, quantitative proteomics, and immune-related factors will also be examined.
By integrating viral, metabolic, protein, immune, and clinical data, this study aims to identify molecular features and potential biomarkers associated with liver inflammation, early liver fibrosis, viral replication, and HBsAg expression. The findings may help improve understanding of differences among patients with chronic HBV infection and provide a basis for future research on risk assessment and disease management.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cross-Sectional Integrated Multi-Omics Study of Treatment-Naive Patients With Chronic Hepatitis B Virus Infection
- Criteria questions
- Built from NCT07935148, who can take part
- Record updated
- 13 November 2026